Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs

Amy Plotkin, Claude Henry Volmar, Claes Wahlestedt, Nagi Ayad, Dorraya El-Ashry

Research output: Contribution to journalArticle

Abstract

Anti-estrogen therapies are not effective in ER− breast cancers, thus identifying mechanisms underlying lack of ER expression in ER− breast cancers is imperative. We have previously demonstrated that hyperactivation of MAPK (hMAPK) downstream of overexpressed EGFR or overexpression/amplification of Her2 represses ER protein and mRNA expression. Abrogation of hMAPK in ER− breast cancer cell lines and primary cultures causes re-expression of ER and restoration of anti-estrogen responses. This study was performed to identify mechanisms of hMAPK-induced transcriptional repression of ER. We found that ER promoter activity is significantly reduced in the presence of hMAPK signaling, yet did not identify specific promoter sequences responsible for this repression. We performed an epigenetic compound screen in an ER− breast cancer cell line that expresses hMAPK yet does not exhibit ER promoter hypermethylation. A number of HDAC inhibitors were identified and confirmed to modulate ER expression and estrogen signaling in multiple ER− cell lines and tumor samples lacking ER promoter methylation. siRNA-mediated knockdown of HDACs 1, 2, and 3 reversed the mRNA repression in multiple breast cancer cell lines and primary cultures and ER promoter-associated histone acetylation increased following MAPK inhibition. These data implicate histone deacetylation downstream of hMAPK in the observed ER mRNA repression associated with hMAPK. Importantly, histone deacetylation appears to be a common mechanism in the transcriptional repression of ER between ER− breast cancers with or without ER promoter hypermethylation.

Original languageEnglish (US)
Pages (from-to)249-263
Number of pages15
JournalBreast Cancer Research and Treatment
Volume147
Issue number2
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Histones
Breast Neoplasms
Estrogens
Cell Line
Messenger RNA
Histone Deacetylase Inhibitors
Acetylation
Tumor Cell Line
Epigenomics
Methylation
Small Interfering RNA
Proteins

Keywords

  • Breast cancer
  • Estrogen receptor
  • HDAC
  • Histone deacetylase inhibitor
  • Hormonal status
  • MAPK
  • Transcriptional repression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs. / Plotkin, Amy; Volmar, Claude Henry; Wahlestedt, Claes; Ayad, Nagi; El-Ashry, Dorraya.

In: Breast Cancer Research and Treatment, Vol. 147, No. 2, 01.09.2014, p. 249-263.

Research output: Contribution to journalArticle

Plotkin, Amy ; Volmar, Claude Henry ; Wahlestedt, Claes ; Ayad, Nagi ; El-Ashry, Dorraya. / Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs. In: Breast Cancer Research and Treatment. 2014 ; Vol. 147, No. 2. pp. 249-263.
@article{082a7b28b36b47d8a9299abf354925e0,
title = "Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs",
abstract = "Anti-estrogen therapies are not effective in ER− breast cancers, thus identifying mechanisms underlying lack of ER expression in ER− breast cancers is imperative. We have previously demonstrated that hyperactivation of MAPK (hMAPK) downstream of overexpressed EGFR or overexpression/amplification of Her2 represses ER protein and mRNA expression. Abrogation of hMAPK in ER− breast cancer cell lines and primary cultures causes re-expression of ER and restoration of anti-estrogen responses. This study was performed to identify mechanisms of hMAPK-induced transcriptional repression of ER. We found that ER promoter activity is significantly reduced in the presence of hMAPK signaling, yet did not identify specific promoter sequences responsible for this repression. We performed an epigenetic compound screen in an ER− breast cancer cell line that expresses hMAPK yet does not exhibit ER promoter hypermethylation. A number of HDAC inhibitors were identified and confirmed to modulate ER expression and estrogen signaling in multiple ER− cell lines and tumor samples lacking ER promoter methylation. siRNA-mediated knockdown of HDACs 1, 2, and 3 reversed the mRNA repression in multiple breast cancer cell lines and primary cultures and ER promoter-associated histone acetylation increased following MAPK inhibition. These data implicate histone deacetylation downstream of hMAPK in the observed ER mRNA repression associated with hMAPK. Importantly, histone deacetylation appears to be a common mechanism in the transcriptional repression of ER between ER− breast cancers with or without ER promoter hypermethylation.",
keywords = "Breast cancer, Estrogen receptor, HDAC, Histone deacetylase inhibitor, Hormonal status, MAPK, Transcriptional repression",
author = "Amy Plotkin and Volmar, {Claude Henry} and Claes Wahlestedt and Nagi Ayad and Dorraya El-Ashry",
year = "2014",
month = "9",
day = "1",
doi = "10.1007/s10549-014-3093-5",
language = "English (US)",
volume = "147",
pages = "249--263",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs

AU - Plotkin, Amy

AU - Volmar, Claude Henry

AU - Wahlestedt, Claes

AU - Ayad, Nagi

AU - El-Ashry, Dorraya

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Anti-estrogen therapies are not effective in ER− breast cancers, thus identifying mechanisms underlying lack of ER expression in ER− breast cancers is imperative. We have previously demonstrated that hyperactivation of MAPK (hMAPK) downstream of overexpressed EGFR or overexpression/amplification of Her2 represses ER protein and mRNA expression. Abrogation of hMAPK in ER− breast cancer cell lines and primary cultures causes re-expression of ER and restoration of anti-estrogen responses. This study was performed to identify mechanisms of hMAPK-induced transcriptional repression of ER. We found that ER promoter activity is significantly reduced in the presence of hMAPK signaling, yet did not identify specific promoter sequences responsible for this repression. We performed an epigenetic compound screen in an ER− breast cancer cell line that expresses hMAPK yet does not exhibit ER promoter hypermethylation. A number of HDAC inhibitors were identified and confirmed to modulate ER expression and estrogen signaling in multiple ER− cell lines and tumor samples lacking ER promoter methylation. siRNA-mediated knockdown of HDACs 1, 2, and 3 reversed the mRNA repression in multiple breast cancer cell lines and primary cultures and ER promoter-associated histone acetylation increased following MAPK inhibition. These data implicate histone deacetylation downstream of hMAPK in the observed ER mRNA repression associated with hMAPK. Importantly, histone deacetylation appears to be a common mechanism in the transcriptional repression of ER between ER− breast cancers with or without ER promoter hypermethylation.

AB - Anti-estrogen therapies are not effective in ER− breast cancers, thus identifying mechanisms underlying lack of ER expression in ER− breast cancers is imperative. We have previously demonstrated that hyperactivation of MAPK (hMAPK) downstream of overexpressed EGFR or overexpression/amplification of Her2 represses ER protein and mRNA expression. Abrogation of hMAPK in ER− breast cancer cell lines and primary cultures causes re-expression of ER and restoration of anti-estrogen responses. This study was performed to identify mechanisms of hMAPK-induced transcriptional repression of ER. We found that ER promoter activity is significantly reduced in the presence of hMAPK signaling, yet did not identify specific promoter sequences responsible for this repression. We performed an epigenetic compound screen in an ER− breast cancer cell line that expresses hMAPK yet does not exhibit ER promoter hypermethylation. A number of HDAC inhibitors were identified and confirmed to modulate ER expression and estrogen signaling in multiple ER− cell lines and tumor samples lacking ER promoter methylation. siRNA-mediated knockdown of HDACs 1, 2, and 3 reversed the mRNA repression in multiple breast cancer cell lines and primary cultures and ER promoter-associated histone acetylation increased following MAPK inhibition. These data implicate histone deacetylation downstream of hMAPK in the observed ER mRNA repression associated with hMAPK. Importantly, histone deacetylation appears to be a common mechanism in the transcriptional repression of ER between ER− breast cancers with or without ER promoter hypermethylation.

KW - Breast cancer

KW - Estrogen receptor

KW - HDAC

KW - Histone deacetylase inhibitor

KW - Hormonal status

KW - MAPK

KW - Transcriptional repression

UR - http://www.scopus.com/inward/record.url?scp=84929989448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929989448&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3093-5

DO - 10.1007/s10549-014-3093-5

M3 - Article

C2 - 25129342

AN - SCOPUS:84929989448

VL - 147

SP - 249

EP - 263

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -